Blanket Purchase Agreement V797D40222-75D30118A02722

The Centers for Disease Control and Prevention (CDC) awarded a Blanket Purchase Agreement (BPA) contract to Abbott Molecular Inc., a subsidiary of Abbott Laboratories, to provide reagents, consumables, and other diagnostic supplies in support of the agency's laboratory testing and disease monitoring capabilities. The $1.25 million single-award contract, issued against the General Services Administration's (GSA) In Vitro Diagnostics, Reagents, and Test (FSS-65-VII) Schedule, has an ultimate completion date of August 13, 2023. The task orders issued under this BPA include the provision of reagent kits, HIV testing supplies, and consumables for use on Abbott's M2000SP and M2000RT molecular diagnostic platforms. These products will be delivered to the CDC's facilities in Georgia and Illinois, enabling the agency to carry out critical disease testing and public health surveillance efforts. As a leading global healthcare manufacturer, Abbott Molecular has a strong track record of supplying a wide range of medical equipment, diagnostic systems, and laboratory consumables to various federal agencies, including the Department of Veterans Affairs and Department of Defense.

The CDC's contract with Abbott Molecular aligns with the agency's mission to protect public health and promote disease prevention. By securing access to a reliable supply of high-quality diagnostic reagents and testing materials, the CDC can enhance its ability to monitor emerging health threats, conduct infectious disease surveillance, and support its overall public health initiatives. The contract's flexible BPA structure allows the CDC to efficiently procure needed supplies through a streamlined acquisition process, rather than relying on individual purchase orders. This approach enables the agency to quickly obtain critical laboratory materials as required to sustain its diagnostic capabilities and responsiveness to evolving healthcare needs.